AAN 2026 18 - 22 April 2026

Semaglutide Impacts Proteomic Signatures Related to Dementia Risk in the SELECT Cardiovascular Outcomes Trial

Authors :

Dylan Belmont-Rausch¹, MartíJiménezMausbach¹, JanChristianRefsgaard¹,GabrielMartino¹,TeresaLeonColombo¹,BettyTijms²,ClarePaterson³

Affiliations

View Details Hide Details

Download .PDF

Keywords

Neurodegenerative diseases

Congress poster

GLP-1 RA

Semaglutide

PHASE 3 (RCT)